| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 125 | 2026 | 1005 | 14.350 |
Why?
|
| Colonic Neoplasms | 78 | 2025 | 164 | 6.770 |
Why?
|
| Colorectal Neoplasms | 67 | 2025 | 642 | 6.160 |
Why?
|
| Neoplasm Recurrence, Local | 45 | 2022 | 248 | 5.690 |
Why?
|
| Body Mass Index | 73 | 2026 | 959 | 5.660 |
Why?
|
| Obesity | 51 | 2026 | 821 | 5.580 |
Why?
|
| Middle Aged | 346 | 2026 | 7954 | 5.310 |
Why?
|
| Postmenopause | 72 | 2026 | 251 | 5.250 |
Why?
|
| Aged | 286 | 2026 | 6223 | 4.780 |
Why?
|
| Female | 391 | 2026 | 12715 | 4.780 |
Why?
|
| Humans | 431 | 2026 | 17622 | 4.580 |
Why?
|
| Diet | 74 | 2022 | 355 | 4.480 |
Why?
|
| Risk Factors | 168 | 2026 | 3291 | 3.710 |
Why?
|
| Adiposity | 14 | 2026 | 71 | 3.680 |
Why?
|
| Weight Gain | 20 | 2020 | 165 | 3.180 |
Why?
|
| Neoplasms | 23 | 2026 | 457 | 3.170 |
Why?
|
| Adult | 209 | 2025 | 7621 | 3.120 |
Why?
|
| Rectal Neoplasms | 35 | 2020 | 75 | 3.090 |
Why?
|
| Proportional Hazards Models | 75 | 2022 | 702 | 3.070 |
Why?
|
| Prognosis | 58 | 2025 | 609 | 2.960 |
Why?
|
| Survivors | 21 | 2016 | 157 | 2.670 |
Why?
|
| Hot Flashes | 20 | 2020 | 38 | 2.630 |
Why?
|
| Neoplasm Staging | 41 | 2022 | 350 | 2.560 |
Why?
|
| Weight Loss | 19 | 2024 | 298 | 2.440 |
Why?
|
| Body Composition | 17 | 2025 | 92 | 2.440 |
Why?
|
| Feeding Behavior | 33 | 2020 | 163 | 2.080 |
Why?
|
| Polymorphism, Single Nucleotide | 43 | 2019 | 369 | 2.040 |
Why?
|
| Exercise | 28 | 2024 | 538 | 2.010 |
Why?
|
| Cohort Studies | 64 | 2022 | 2502 | 2.010 |
Why?
|
| Cardiovascular Diseases | 15 | 2023 | 545 | 1.940 |
Why?
|
| Women's Health | 32 | 2026 | 198 | 1.930 |
Why?
|
| Male | 179 | 2025 | 10014 | 1.920 |
Why?
|
| Life Style | 38 | 2022 | 321 | 1.860 |
Why?
|
| Surveys and Questionnaires | 58 | 2020 | 1296 | 1.850 |
Why?
|
| Estrogens | 18 | 2018 | 60 | 1.700 |
Why?
|
| Follow-Up Studies | 53 | 2025 | 1157 | 1.680 |
Why?
|
| California | 59 | 2025 | 2433 | 1.660 |
Why?
|
| Genetic Predisposition to Disease | 42 | 2019 | 384 | 1.650 |
Why?
|
| Dietary Fats | 22 | 2013 | 89 | 1.630 |
Why?
|
| Case-Control Studies | 86 | 2019 | 1107 | 1.610 |
Why?
|
| Prospective Studies | 43 | 2025 | 1251 | 1.590 |
Why?
|
| Carcinoma, Ductal, Breast | 6 | 2015 | 53 | 1.590 |
Why?
|
| Cause of Death | 11 | 2021 | 179 | 1.590 |
Why?
|
| Muscle, Skeletal | 12 | 2025 | 36 | 1.580 |
Why?
|
| Dietary Supplements | 14 | 2015 | 85 | 1.520 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2015 | 50 | 1.510 |
Why?
|
| Odds Ratio | 50 | 2019 | 631 | 1.450 |
Why?
|
| United States | 69 | 2021 | 3922 | 1.400 |
Why?
|
| Estrogen Replacement Therapy | 18 | 2016 | 100 | 1.400 |
Why?
|
| Diabetes, Gestational | 11 | 2018 | 328 | 1.350 |
Why?
|
| Aged, 80 and over | 37 | 2025 | 1976 | 1.320 |
Why?
|
| Body Weight | 15 | 2021 | 203 | 1.300 |
Why?
|
| Survival Analysis | 19 | 2024 | 197 | 1.280 |
Why?
|
| Incidence | 45 | 2026 | 1278 | 1.280 |
Why?
|
| Mortality | 9 | 2021 | 116 | 1.260 |
Why?
|
| Risk Assessment | 40 | 2020 | 1093 | 1.240 |
Why?
|
| Genetic Variation | 15 | 2016 | 82 | 1.240 |
Why?
|
| Biomarkers, Tumor | 12 | 2025 | 148 | 1.230 |
Why?
|
| Menopause | 11 | 2020 | 68 | 1.220 |
Why?
|
| Quality of Life | 13 | 2024 | 505 | 1.180 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2025 | 215 | 1.140 |
Why?
|
| Young Adult | 31 | 2025 | 2538 | 1.130 |
Why?
|
| Alcohol Drinking | 16 | 2020 | 354 | 1.130 |
Why?
|
| Diet, Fat-Restricted | 18 | 2009 | 36 | 1.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2019 | 168 | 1.070 |
Why?
|
| Energy Intake | 25 | 2020 | 97 | 1.060 |
Why?
|
| Smoking | 20 | 2017 | 420 | 1.060 |
Why?
|
| Overweight | 12 | 2022 | 266 | 1.060 |
Why?
|
| Receptors, Estrogen | 7 | 2017 | 53 | 1.060 |
Why?
|
| Genotype | 51 | 2018 | 224 | 1.040 |
Why?
|
| Estradiol | 7 | 2018 | 23 | 1.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 60 | 1.010 |
Why?
|
| Inflammation | 9 | 2025 | 60 | 0.990 |
Why?
|
| Social Support | 6 | 2020 | 215 | 0.980 |
Why?
|
| Ethnic Groups | 11 | 2016 | 443 | 0.970 |
Why?
|
| Intra-Abdominal Fat | 9 | 2026 | 17 | 0.970 |
Why?
|
| Randomized Controlled Trials as Topic | 21 | 2020 | 323 | 0.950 |
Why?
|
| Diet Records | 19 | 2021 | 37 | 0.950 |
Why?
|
| Polymorphism, Genetic | 24 | 2012 | 61 | 0.950 |
Why?
|
| Receptors, Progesterone | 7 | 2017 | 50 | 0.950 |
Why?
|
| Genome-Wide Association Study | 19 | 2018 | 255 | 0.930 |
Why?
|
| Vitamin D | 12 | 2013 | 76 | 0.920 |
Why?
|
| Treatment Outcome | 25 | 2025 | 1161 | 0.910 |
Why?
|
| Absorptiometry, Photon | 6 | 2026 | 54 | 0.900 |
Why?
|
| Sarcopenia | 3 | 2024 | 11 | 0.890 |
Why?
|
| Adolescent | 32 | 2025 | 3625 | 0.890 |
Why?
|
| Cancer Survivors | 5 | 2024 | 115 | 0.890 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 14 | 2015 | 64 | 0.880 |
Why?
|
| Dairy Products | 6 | 2013 | 22 | 0.870 |
Why?
|
| Time Factors | 26 | 2017 | 1038 | 0.870 |
Why?
|
| Frailty | 2 | 2024 | 12 | 0.870 |
Why?
|
| Diet Surveys | 17 | 2020 | 56 | 0.870 |
Why?
|
| Vitamins | 6 | 2022 | 59 | 0.860 |
Why?
|
| Multivariate Analysis | 15 | 2020 | 527 | 0.830 |
Why?
|
| Logistic Models | 37 | 2020 | 866 | 0.830 |
Why?
|
| Soy Foods | 4 | 2013 | 10 | 0.820 |
Why?
|
| Retrospective Studies | 20 | 2025 | 2502 | 0.820 |
Why?
|
| Carotenoids | 17 | 2011 | 28 | 0.790 |
Why?
|
| Vegetables | 22 | 2020 | 88 | 0.780 |
Why?
|
| Continental Population Groups | 13 | 2016 | 283 | 0.780 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 63 | 0.780 |
Why?
|
| Mutation | 16 | 2011 | 133 | 0.750 |
Why?
|
| Registries | 16 | 2020 | 475 | 0.750 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 16 | 0.740 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 22 | 0.740 |
Why?
|
| Neoplasm Invasiveness | 11 | 2017 | 80 | 0.740 |
Why?
|
| Comorbidity | 14 | 2020 | 552 | 0.730 |
Why?
|
| Medroxyprogesterone Acetate | 6 | 2010 | 15 | 0.730 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 36 | 0.720 |
Why?
|
| Estrogen Receptor alpha | 4 | 2015 | 25 | 0.710 |
Why?
|
| Health Behavior | 13 | 2010 | 348 | 0.710 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2017 | 120 | 0.710 |
Why?
|
| Obesity, Abdominal | 4 | 2026 | 14 | 0.690 |
Why?
|
| Serotonin Uptake Inhibitors | 5 | 2015 | 45 | 0.690 |
Why?
|
| Biomarkers | 15 | 2025 | 302 | 0.690 |
Why?
|
| Age Factors | 19 | 2020 | 874 | 0.680 |
Why?
|
| Endometrial Neoplasms | 6 | 2020 | 37 | 0.680 |
Why?
|
| Epidemiologic Methods | 9 | 2017 | 70 | 0.660 |
Why?
|
| Adenoma | 14 | 2013 | 98 | 0.660 |
Why?
|
| Taxoids | 2 | 2020 | 8 | 0.650 |
Why?
|
| Metabolic Equivalent | 2 | 2020 | 8 | 0.650 |
Why?
|
| Anthracyclines | 2 | 2020 | 14 | 0.650 |
Why?
|
| Diabetes Mellitus | 9 | 2022 | 452 | 0.640 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 4 | 0.630 |
Why?
|
| Depression | 8 | 2022 | 507 | 0.630 |
Why?
|
| Prostatic Neoplasms | 5 | 2010 | 262 | 0.620 |
Why?
|
| Risk | 26 | 2019 | 492 | 0.610 |
Why?
|
| Cholecalciferol | 4 | 2012 | 16 | 0.610 |
Why?
|
| Tissue Distribution | 1 | 2019 | 7 | 0.610 |
Why?
|
| Motor Activity | 9 | 2014 | 207 | 0.610 |
Why?
|
| Survival Rate | 17 | 2019 | 252 | 0.590 |
Why?
|
| Double-Blind Method | 19 | 2015 | 144 | 0.590 |
Why?
|
| Gene-Environment Interaction | 6 | 2017 | 21 | 0.580 |
Why?
|
| Aspirin | 10 | 2015 | 63 | 0.580 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 7 | 0.580 |
Why?
|
| Calcium, Dietary | 8 | 2012 | 28 | 0.570 |
Why?
|
| Venlafaxine Hydrochloride | 5 | 2015 | 20 | 0.570 |
Why?
|
| Hormone Replacement Therapy | 6 | 2010 | 20 | 0.560 |
Why?
|
| Pregnancy | 19 | 2022 | 1565 | 0.560 |
Why?
|
| DNA, Neoplasm | 7 | 2013 | 20 | 0.550 |
Why?
|
| Dietary Fiber | 19 | 2014 | 60 | 0.550 |
Why?
|
| Research Design | 9 | 2020 | 337 | 0.550 |
Why?
|
| Social Networking | 3 | 2013 | 20 | 0.550 |
Why?
|
| Signal Transduction | 6 | 2018 | 33 | 0.530 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 37 | 0.520 |
Why?
|
| Yoga | 7 | 2017 | 25 | 0.520 |
Why?
|
| Receptor, ErbB-2 | 5 | 2017 | 47 | 0.520 |
Why?
|
| Medication Adherence | 1 | 2020 | 232 | 0.520 |
Why?
|
| Fruit | 19 | 2020 | 79 | 0.510 |
Why?
|
| European Continental Ancestry Group | 21 | 2016 | 470 | 0.500 |
Why?
|
| Pregnancy Trimesters | 1 | 2016 | 29 | 0.500 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2012 | 65 | 0.500 |
Why?
|
| Receptors, Calcitriol | 10 | 2010 | 12 | 0.490 |
Why?
|
| Sex Factors | 24 | 2020 | 599 | 0.480 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2020 | 122 | 0.480 |
Why?
|
| Prenatal Care | 2 | 2016 | 129 | 0.480 |
Why?
|
| Energy Metabolism | 10 | 2011 | 48 | 0.470 |
Why?
|
| Lymph Nodes | 1 | 2016 | 17 | 0.470 |
Why?
|
| Maternal Exposure | 1 | 2016 | 84 | 0.470 |
Why?
|
| Antioxidants | 7 | 2011 | 40 | 0.470 |
Why?
|
| Patient Compliance | 9 | 2014 | 269 | 0.470 |
Why?
|
| Adipose Tissue | 7 | 2024 | 67 | 0.460 |
Why?
|
| Caffeine | 6 | 1999 | 18 | 0.450 |
Why?
|
| Medical Records | 1 | 2015 | 91 | 0.450 |
Why?
|
| Eating | 8 | 2020 | 34 | 0.450 |
Why?
|
| Vitamin E | 6 | 2011 | 20 | 0.440 |
Why?
|
| Cachexia | 4 | 2025 | 4 | 0.440 |
Why?
|
| Resistance Training | 2 | 2025 | 5 | 0.440 |
Why?
|
| C-Reactive Protein | 7 | 2025 | 56 | 0.440 |
Why?
|
| Confidence Intervals | 13 | 2016 | 228 | 0.440 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2014 | 21 | 0.440 |
Why?
|
| Microsatellite Instability | 10 | 2015 | 16 | 0.440 |
Why?
|
| Interleukin-6 | 5 | 2025 | 24 | 0.430 |
Why?
|
| China | 7 | 2016 | 132 | 0.430 |
Why?
|
| Chi-Square Distribution | 11 | 2017 | 144 | 0.430 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2011 | 20 | 0.430 |
Why?
|
| Utah | 15 | 2014 | 38 | 0.430 |
Why?
|
| Algorithms | 2 | 2015 | 227 | 0.430 |
Why?
|
| Anticarcinogenic Agents | 4 | 2013 | 13 | 0.420 |
Why?
|
| African Americans | 16 | 2016 | 429 | 0.420 |
Why?
|
| Severity of Illness Index | 7 | 2020 | 446 | 0.410 |
Why?
|
| Mammography | 5 | 2015 | 173 | 0.410 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2016 | 205 | 0.410 |
Why?
|
| Progestins | 5 | 2016 | 25 | 0.410 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2014 | 24 | 0.410 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2014 | 689 | 0.410 |
Why?
|
| Breast Feeding | 1 | 2015 | 119 | 0.410 |
Why?
|
| Bone Density Conservation Agents | 3 | 2011 | 55 | 0.400 |
Why?
|
| Isoflavones | 2 | 2013 | 14 | 0.390 |
Why?
|
| Activities of Daily Living | 2 | 2010 | 80 | 0.390 |
Why?
|
| Recurrence | 11 | 2014 | 166 | 0.390 |
Why?
|
| Thinness | 2 | 2013 | 31 | 0.380 |
Why?
|
| Bariatric Surgery | 4 | 2024 | 133 | 0.380 |
Why?
|
| Hypertension | 4 | 2022 | 486 | 0.380 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 5 | 2020 | 35 | 0.370 |
Why?
|
| Health Status | 5 | 2009 | 291 | 0.370 |
Why?
|
| Drug Administration Schedule | 5 | 2017 | 99 | 0.370 |
Why?
|
| Guideline Adherence | 5 | 2021 | 155 | 0.370 |
Why?
|
| Fatty Acids, Omega-3 | 5 | 2015 | 21 | 0.370 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2012 | 1 | 0.370 |
Why?
|
| Meat | 8 | 2014 | 27 | 0.370 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2012 | 2 | 0.370 |
Why?
|
| Adenomatous Polyps | 8 | 2008 | 16 | 0.360 |
Why?
|
| Cyclohexanols | 4 | 2015 | 19 | 0.360 |
Why?
|
| Databases, Factual | 5 | 2017 | 304 | 0.360 |
Why?
|
| Lung Neoplasms | 3 | 2025 | 278 | 0.350 |
Why?
|
| CpG Islands | 12 | 2011 | 22 | 0.350 |
Why?
|
| Folic Acid | 5 | 2022 | 29 | 0.350 |
Why?
|
| Disease-Free Survival | 8 | 2016 | 55 | 0.350 |
Why?
|
| DNA Methylation | 10 | 2011 | 45 | 0.340 |
Why?
|
| Reproducibility of Results | 11 | 2025 | 363 | 0.340 |
Why?
|
| Colonic Polyps | 9 | 2008 | 36 | 0.340 |
Why?
|
| Proto-Oncogene Proteins | 9 | 2011 | 32 | 0.330 |
Why?
|
| Patient Selection | 7 | 2019 | 181 | 0.330 |
Why?
|
| Fatigue | 2 | 2020 | 30 | 0.330 |
Why?
|
| Leucovorin | 2 | 2022 | 5 | 0.320 |
Why?
|
| Epigenesis, Genetic | 5 | 2010 | 26 | 0.320 |
Why?
|
| Fluorouracil | 2 | 2022 | 11 | 0.320 |
Why?
|
| Pancreatic Neoplasms | 2 | 2023 | 71 | 0.310 |
Why?
|
| Mass Screening | 3 | 2009 | 693 | 0.310 |
Why?
|
| Pregnancy Complications | 3 | 2020 | 208 | 0.310 |
Why?
|
| Hispanic Americans | 12 | 2020 | 370 | 0.310 |
Why?
|
| Perimenopause | 5 | 2015 | 11 | 0.310 |
Why?
|
| Coronary Disease | 10 | 2006 | 145 | 0.300 |
Why?
|
| Dietary Proteins | 5 | 2015 | 20 | 0.300 |
Why?
|
| Prevalence | 10 | 2017 | 830 | 0.300 |
Why?
|
| Colectomy | 2 | 2020 | 31 | 0.290 |
Why?
|
| Calcium Compounds | 1 | 2008 | 3 | 0.290 |
Why?
|
| Proto-Oncogene Proteins B-raf | 7 | 2009 | 15 | 0.290 |
Why?
|
| ras Proteins | 9 | 2011 | 20 | 0.290 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 25 | 0.290 |
Why?
|
| Calcium | 5 | 2012 | 30 | 0.290 |
Why?
|
| Ovarian Neoplasms | 3 | 2020 | 53 | 0.280 |
Why?
|
| Ibuprofen | 2 | 2009 | 9 | 0.280 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2008 | 8 | 0.280 |
Why?
|
| Environment | 4 | 2019 | 50 | 0.280 |
Why?
|
| Tamoxifen | 3 | 2010 | 55 | 0.280 |
Why?
|
| Psychometrics | 1 | 2008 | 119 | 0.280 |
Why?
|
| Multiple Myeloma | 2 | 2023 | 10 | 0.270 |
Why?
|
| Adenocarcinoma | 4 | 2016 | 172 | 0.270 |
Why?
|
| Insulin Resistance | 4 | 2014 | 128 | 0.270 |
Why?
|
| Cholesterol | 10 | 2023 | 82 | 0.270 |
Why?
|
| Arylamine N-Acetyltransferase | 8 | 2014 | 10 | 0.270 |
Why?
|
| Nutrition Assessment | 8 | 2009 | 26 | 0.270 |
Why?
|
| Software | 2 | 2025 | 19 | 0.270 |
Why?
|
| Analysis of Variance | 5 | 2018 | 137 | 0.270 |
Why?
|
| Sleep | 4 | 2017 | 56 | 0.260 |
Why?
|
| Insurance Carriers | 1 | 2007 | 6 | 0.260 |
Why?
|
| Organizations, Nonprofit | 1 | 2007 | 11 | 0.260 |
Why?
|
| Models, Statistical | 4 | 2017 | 171 | 0.260 |
Why?
|
| Sigmoidoscopy | 1 | 2007 | 65 | 0.260 |
Why?
|
| Basal Metabolism | 2 | 2004 | 5 | 0.260 |
Why?
|
| Outcome Assessment (Health Care) | 5 | 2018 | 213 | 0.250 |
Why?
|
| Alleles | 7 | 2014 | 80 | 0.250 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 3 | 0.250 |
Why?
|
| Cell Proliferation | 4 | 2020 | 19 | 0.250 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2006 | 10 | 0.250 |
Why?
|
| Blood Glucose | 7 | 2014 | 319 | 0.250 |
Why?
|
| Carcinoma | 3 | 2011 | 22 | 0.250 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2006 | 17 | 0.250 |
Why?
|
| Prepaid Health Plans | 1 | 2006 | 18 | 0.240 |
Why?
|
| Lutein | 5 | 2010 | 7 | 0.240 |
Why?
|
| Genes, p53 | 5 | 2010 | 7 | 0.240 |
Why?
|
| Genetic Loci | 4 | 2014 | 54 | 0.240 |
Why?
|
| Subcutaneous Fat | 1 | 2026 | 4 | 0.240 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 37 | 0.240 |
Why?
|
| Residence Characteristics | 5 | 2016 | 256 | 0.240 |
Why?
|
| Combined Modality Therapy | 3 | 2016 | 114 | 0.240 |
Why?
|
| Colonoscopy | 7 | 2018 | 265 | 0.240 |
Why?
|
| Adaptor Proteins, Signal Transducing | 7 | 2009 | 15 | 0.240 |
Why?
|
| Asian Americans | 6 | 2016 | 160 | 0.240 |
Why?
|
| Thoracic Vertebrae | 1 | 2025 | 2 | 0.230 |
Why?
|
| Food | 4 | 2006 | 36 | 0.230 |
Why?
|
| Fibric Acids | 1 | 2025 | 2 | 0.230 |
Why?
|
| RNA, Messenger | 3 | 2014 | 72 | 0.230 |
Why?
|
| Xanthophylls | 4 | 2010 | 6 | 0.230 |
Why?
|
| DNA Repair | 2 | 2019 | 10 | 0.230 |
Why?
|
| Stroke | 5 | 2016 | 309 | 0.230 |
Why?
|
| DNA-Binding Proteins | 5 | 2019 | 30 | 0.230 |
Why?
|
| Citalopram | 3 | 2015 | 9 | 0.230 |
Why?
|
| Colitis, Ulcerative | 2 | 2015 | 8 | 0.220 |
Why?
|
| Crohn Disease | 2 | 2015 | 12 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 8 | 2013 | 51 | 0.220 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 5 | 2012 | 8 | 0.220 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2024 | 9 | 0.220 |
Why?
|
| Vaginal Diseases | 3 | 2020 | 6 | 0.220 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 54 | 0.220 |
Why?
|
| Independent Living | 2 | 2024 | 24 | 0.210 |
Why?
|
| Hand Strength | 1 | 2024 | 10 | 0.210 |
Why?
|
| Cross-Sectional Studies | 11 | 2020 | 1295 | 0.210 |
Why?
|
| Health Promotion | 2 | 2020 | 293 | 0.210 |
Why?
|
| Creatine | 1 | 2024 | 3 | 0.210 |
Why?
|
| Phenotype | 13 | 2011 | 154 | 0.210 |
Why?
|
| Health Maintenance Organizations | 4 | 2012 | 403 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2025 | 87 | 0.210 |
Why?
|
| Myocardial Infarction | 3 | 2020 | 226 | 0.210 |
Why?
|
| Regression Analysis | 9 | 2011 | 268 | 0.210 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 22 | 0.210 |
Why?
|
| Fractures, Bone | 4 | 2006 | 93 | 0.210 |
Why?
|
| Aging | 3 | 2019 | 159 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 27 | 0.210 |
Why?
|
| Sensitivity and Specificity | 6 | 2015 | 302 | 0.210 |
Why?
|
| Obesity, Morbid | 3 | 2013 | 121 | 0.210 |
Why?
|
| Cholesterol, HDL | 4 | 2023 | 68 | 0.210 |
Why?
|
| Age Distribution | 9 | 2012 | 230 | 0.210 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 346 | 0.210 |
Why?
|
| Socioeconomic Factors | 9 | 2016 | 603 | 0.210 |
Why?
|
| Brassicaceae | 3 | 2013 | 7 | 0.200 |
Why?
|
| Macular Degeneration | 2 | 2010 | 20 | 0.200 |
Why?
|
| Bias | 3 | 2018 | 95 | 0.200 |
Why?
|
| Postpartum Period | 3 | 2018 | 93 | 0.200 |
Why?
|
| Prostate-Specific Antigen | 3 | 2009 | 74 | 0.200 |
Why?
|
| Calcium Carbonate | 3 | 2010 | 9 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 368 | 0.200 |
Why?
|
| Adiponectin | 1 | 2013 | 21 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2024 | 27 | 0.200 |
Why?
|
| Antidepressive Agents | 2 | 2017 | 142 | 0.200 |
Why?
|
| Electronic Health Records | 3 | 2018 | 719 | 0.190 |
Why?
|
| Ideal Body Weight | 2 | 2020 | 10 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 3 | 2011 | 8 | 0.190 |
Why?
|
| Risk Reduction Behavior | 4 | 2020 | 102 | 0.190 |
Why?
|
| Haplotypes | 4 | 2011 | 34 | 0.180 |
Why?
|
| Abdominal Fat | 2 | 2026 | 14 | 0.180 |
Why?
|
| Men's Health | 3 | 2019 | 20 | 0.180 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2022 | 8 | 0.180 |
Why?
|
| Glutathione Transferase | 7 | 2009 | 13 | 0.180 |
Why?
|
| Prehypertension | 1 | 2012 | 21 | 0.180 |
Why?
|
| Nuclear Proteins | 4 | 2009 | 11 | 0.180 |
Why?
|
| Cost of Illness | 2 | 2012 | 92 | 0.180 |
Why?
|
| Insulin | 5 | 2011 | 188 | 0.180 |
Why?
|
| Mentoring | 1 | 2022 | 29 | 0.180 |
Why?
|
| Disease Progression | 2 | 2020 | 266 | 0.180 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2012 | 40 | 0.180 |
Why?
|
| Coronary Artery Disease | 4 | 2016 | 112 | 0.170 |
Why?
|
| Vitamin A | 3 | 2009 | 14 | 0.170 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2019 | 2 | 0.170 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 9 | 2011 | 21 | 0.170 |
Why?
|
| Nutrition Policy | 1 | 2021 | 18 | 0.170 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2011 | 13 | 0.170 |
Why?
|
| Organ Size | 2 | 2018 | 16 | 0.170 |
Why?
|
| Mental Recall | 8 | 2011 | 28 | 0.170 |
Why?
|
| Self Report | 3 | 2016 | 262 | 0.170 |
Why?
|
| Wine | 3 | 2010 | 18 | 0.170 |
Why?
|
| Nutritional Status | 2 | 2020 | 32 | 0.170 |
Why?
|
| Family Characteristics | 2 | 2012 | 70 | 0.170 |
Why?
|
| Longitudinal Studies | 11 | 2019 | 686 | 0.170 |
Why?
|
| Muscle Weakness | 1 | 2020 | 3 | 0.160 |
Why?
|
| Recommended Dietary Allowances | 1 | 2020 | 2 | 0.160 |
Why?
|
| Monocytes | 1 | 2020 | 4 | 0.160 |
Why?
|
| Triglycerides | 5 | 2022 | 81 | 0.160 |
Why?
|
| Mobility Limitation | 1 | 2020 | 16 | 0.160 |
Why?
|
| Causality | 2 | 2019 | 35 | 0.160 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2020 | 3 | 0.160 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 16 | 0.160 |
Why?
|
| Insurance Claim Review | 2 | 2017 | 49 | 0.160 |
Why?
|
| Leukocyte Count | 2 | 2012 | 24 | 0.160 |
Why?
|
| Models, Genetic | 2 | 2018 | 23 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 2 | 2010 | 2 | 0.160 |
Why?
|
| Minnesota | 7 | 2011 | 51 | 0.150 |
Why?
|
| Dietary Carbohydrates | 6 | 2011 | 28 | 0.150 |
Why?
|
| Body Weights and Measures | 2 | 2017 | 13 | 0.150 |
Why?
|
| Early Detection of Cancer | 2 | 2018 | 559 | 0.150 |
Why?
|
| Statistics, Nonparametric | 2 | 2017 | 46 | 0.150 |
Why?
|
| Lumbosacral Region | 1 | 2019 | 2 | 0.150 |
Why?
|
| Heart Failure | 2 | 2016 | 414 | 0.150 |
Why?
|
| Ethanol | 1 | 2019 | 21 | 0.150 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 18 | 0.150 |
Why?
|
| Social Media | 1 | 2019 | 11 | 0.150 |
Why?
|
| Glycemic Index | 3 | 2008 | 19 | 0.150 |
Why?
|
| Vasomotor System | 2 | 2015 | 4 | 0.150 |
Why?
|
| Body Constitution | 2 | 1998 | 39 | 0.140 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2007 | 12 | 0.140 |
Why?
|
| Animals | 8 | 2020 | 285 | 0.140 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 121 | 0.140 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2018 | 1 | 0.140 |
Why?
|
| Vulva | 1 | 2018 | 1 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 319 | 0.140 |
Why?
|
| Vitamin D3 24-Hydroxylase | 2 | 2016 | 2 | 0.140 |
Why?
|
| Plasma | 1 | 2008 | 1 | 0.140 |
Why?
|
| Melanoma | 1 | 2018 | 37 | 0.140 |
Why?
|
| Cholesterol, LDL | 3 | 2022 | 117 | 0.140 |
Why?
|
| Counseling | 5 | 2007 | 173 | 0.140 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 104 | 0.140 |
Why?
|
| Fertility | 1 | 1998 | 8 | 0.140 |
Why?
|
| Models, Biological | 1 | 2018 | 27 | 0.140 |
Why?
|
| Survivorship | 1 | 2018 | 12 | 0.140 |
Why?
|
| Diet, Reducing | 2 | 2012 | 22 | 0.140 |
Why?
|
| Genomics | 1 | 2018 | 56 | 0.140 |
Why?
|
| Ascorbic Acid | 3 | 2011 | 18 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2018 | 31 | 0.130 |
Why?
|
| Sunlight | 4 | 2010 | 13 | 0.130 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 3 | 0.130 |
Why?
|
| Plants, Edible | 1 | 1997 | 6 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2017 | 26 | 0.130 |
Why?
|
| Gene Frequency | 6 | 2015 | 39 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 8 | 2008 | 80 | 0.130 |
Why?
|
| Infant, Newborn | 3 | 2016 | 842 | 0.130 |
Why?
|
| Affect | 2 | 2014 | 21 | 0.130 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2007 | 11 | 0.130 |
Why?
|
| Weight Reduction Programs | 1 | 2018 | 51 | 0.130 |
Why?
|
| Acculturation | 2 | 2015 | 18 | 0.130 |
Why?
|
| Androgens | 1 | 2007 | 14 | 0.130 |
Why?
|
| Lipids | 3 | 1996 | 69 | 0.130 |
Why?
|
| Actigraphy | 1 | 2017 | 14 | 0.130 |
Why?
|
| Transcriptome | 1 | 2017 | 26 | 0.130 |
Why?
|
| beta Carotene | 5 | 2009 | 17 | 0.130 |
Why?
|
| Thymidylate Synthase | 2 | 2007 | 2 | 0.120 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 33 | 0.120 |
Why?
|
| Lymphatic Metastasis | 3 | 2012 | 30 | 0.120 |
Why?
|
| Protective Factors | 1 | 2016 | 32 | 0.120 |
Why?
|
| Heart Valve Diseases | 1 | 2016 | 17 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2016 | 30 | 0.120 |
Why?
|
| Receptors, Androgen | 2 | 2006 | 9 | 0.120 |
Why?
|
| Factor Analysis, Statistical | 3 | 2008 | 35 | 0.120 |
Why?
|
| Heart Rate | 1 | 2015 | 36 | 0.120 |
Why?
|
| Social Isolation | 1 | 2016 | 20 | 0.120 |
Why?
|
| DNA Repair Enzymes | 2 | 2019 | 6 | 0.120 |
Why?
|
| Tocopherols | 3 | 2010 | 5 | 0.120 |
Why?
|
| Family | 2 | 2012 | 111 | 0.120 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2015 | 1 | 0.110 |
Why?
|
| Bone Morphogenetic Protein 1 | 1 | 2015 | 1 | 0.110 |
Why?
|
| Genetic Association Studies | 5 | 2015 | 33 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2017 | 186 | 0.110 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2015 | 26 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 1996 | 149 | 0.110 |
Why?
|
| PPAR gamma | 2 | 2005 | 9 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2025 | 5 | 0.110 |
Why?
|
| Carcinoma, Lobular | 2 | 2012 | 10 | 0.110 |
Why?
|
| Drug Combinations | 3 | 2010 | 42 | 0.110 |
Why?
|
| MutL Protein Homolog 1 | 5 | 2019 | 8 | 0.110 |
Why?
|
| Premenopause | 2 | 2020 | 24 | 0.110 |
Why?
|
| Docosahexaenoic Acids | 2 | 2014 | 7 | 0.110 |
Why?
|
| Managed Care Programs | 1 | 2016 | 300 | 0.110 |
Why?
|
| Emigration and Immigration | 1 | 2015 | 15 | 0.110 |
Why?
|
| Anthropometry | 3 | 2024 | 59 | 0.110 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2014 | 9 | 0.110 |
Why?
|
| Fertilization | 1 | 1994 | 3 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2013 | 6 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2014 | 17 | 0.110 |
Why?
|
| Recreation | 1 | 2015 | 39 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 4 | 0.110 |
Why?
|
| Behavior Therapy | 1 | 2015 | 125 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 4 | 2011 | 8 | 0.110 |
Why?
|
| Glaucoma | 1 | 2014 | 11 | 0.110 |
Why?
|
| Body Size | 3 | 2016 | 31 | 0.110 |
Why?
|
| Telephone | 4 | 2014 | 159 | 0.100 |
Why?
|
| Sampling Studies | 2 | 2010 | 43 | 0.100 |
Why?
|
| Cyclooxygenase 1 | 1 | 2013 | 1 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 6 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 50 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 208 | 0.100 |
Why?
|
| Genetic Pleiotropy | 1 | 2013 | 9 | 0.100 |
Why?
|
| Premenstrual Syndrome | 1 | 1993 | 2 | 0.100 |
Why?
|
| Data Collection | 4 | 2002 | 234 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2014 | 77 | 0.100 |
Why?
|
| Cyclin D2 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 3 | 0.100 |
Why?
|
| Linear Models | 4 | 2018 | 204 | 0.100 |
Why?
|
| Tumor Burden | 2 | 2012 | 18 | 0.100 |
Why?
|
| Infant | 1 | 2016 | 1228 | 0.100 |
Why?
|
| Progesterone Congeners | 1 | 2002 | 5 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2016 | 1455 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 24 | 0.090 |
Why?
|
| Population Groups | 1 | 2012 | 7 | 0.090 |
Why?
|
| Geriatric Assessment | 2 | 2024 | 42 | 0.090 |
Why?
|
| Genome, Human | 1 | 2012 | 33 | 0.090 |
Why?
|
| Bone Density | 3 | 2006 | 96 | 0.090 |
Why?
|
| Pedigree | 1 | 2012 | 65 | 0.090 |
Why?
|
| Genetic Markers | 4 | 2015 | 23 | 0.090 |
Why?
|
| Glutathione Peroxidase | 1 | 2012 | 3 | 0.090 |
Why?
|
| Marital Status | 1 | 2012 | 20 | 0.090 |
Why?
|
| Genes, ras | 2 | 2009 | 5 | 0.090 |
Why?
|
| Religion | 1 | 2012 | 19 | 0.090 |
Why?
|
| Health Surveys | 2 | 2018 | 242 | 0.090 |
Why?
|
| Receptors, Interleukin | 1 | 2011 | 4 | 0.090 |
Why?
|
| Metabolic Syndrome | 1 | 2012 | 64 | 0.090 |
Why?
|
| TCF Transcription Factors | 2 | 2008 | 9 | 0.090 |
Why?
|
| Community Participation | 1 | 1991 | 29 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 173 | 0.090 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2011 | 3 | 0.090 |
Why?
|
| Nutritional Physiological Phenomena | 2 | 1991 | 14 | 0.090 |
Why?
|
| Aromatase | 1 | 2011 | 9 | 0.090 |
Why?
|
| Phosphoproteins | 3 | 2008 | 3 | 0.090 |
Why?
|
| Caregivers | 1 | 2012 | 136 | 0.090 |
Why?
|
| Beverages | 3 | 2004 | 18 | 0.080 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2010 | 1 | 0.080 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2010 | 1 | 0.080 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2010 | 1 | 0.080 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2010 | 1 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 2 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2010 | 6 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 45 | 0.080 |
Why?
|
| Physical Fitness | 2 | 2002 | 68 | 0.080 |
Why?
|
| Coronary Angiography | 1 | 2010 | 17 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 84 | 0.080 |
Why?
|
| Calcinosis | 1 | 2010 | 35 | 0.080 |
Why?
|
| Preventive Health Services | 1 | 2012 | 147 | 0.080 |
Why?
|
| Population Surveillance | 3 | 2016 | 248 | 0.080 |
Why?
|
| Dietary Sucrose | 3 | 2006 | 13 | 0.080 |
Why?
|
| Sweating | 3 | 2015 | 8 | 0.080 |
Why?
|
| Smad7 Protein | 1 | 2010 | 2 | 0.080 |
Why?
|
| Sex Distribution | 5 | 2012 | 174 | 0.080 |
Why?
|
| Prostatitis | 1 | 2010 | 5 | 0.080 |
Why?
|
| Linkage Disequilibrium | 4 | 2012 | 28 | 0.080 |
Why?
|
| Chemoprevention | 2 | 2007 | 12 | 0.080 |
Why?
|
| Leukemia | 1 | 2009 | 9 | 0.080 |
Why?
|
| Embryonic and Fetal Development | 1 | 1989 | 4 | 0.080 |
Why?
|
| Steroid Hydroxylases | 1 | 2009 | 1 | 0.080 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2009 | 1 | 0.080 |
Why?
|
| Migraine Disorders | 1 | 2010 | 18 | 0.080 |
Why?
|
| Erectile Dysfunction | 1 | 2009 | 23 | 0.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2009 | 23 | 0.080 |
Why?
|
| Infant, Low Birth Weight | 1 | 1989 | 30 | 0.080 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2010 | 52 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 163 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2008 | 6 | 0.080 |
Why?
|
| Precancerous Conditions | 2 | 2008 | 48 | 0.070 |
Why?
|
| Interviews as Topic | 6 | 2005 | 324 | 0.070 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2008 | 1 | 0.070 |
Why?
|
| Quality Control | 5 | 2014 | 40 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 15 | 0.070 |
Why?
|
| Self-Assessment | 1 | 2008 | 14 | 0.070 |
Why?
|
| Observational Studies as Topic | 2 | 2019 | 46 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 3 | 2005 | 28 | 0.070 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2008 | 5 | 0.070 |
Why?
|
| African Continental Ancestry Group | 4 | 2009 | 140 | 0.070 |
Why?
|
| DNA Mismatch Repair | 1 | 2008 | 6 | 0.070 |
Why?
|
| Flavonoids | 1 | 2008 | 7 | 0.070 |
Why?
|
| Receptors, Leptin | 1 | 2008 | 2 | 0.070 |
Why?
|
| Zeaxanthins | 3 | 2010 | 5 | 0.070 |
Why?
|
| Lens Nucleus, Crystalline | 1 | 2008 | 1 | 0.070 |
Why?
|
| Leptin | 1 | 2008 | 26 | 0.070 |
Why?
|
| Reproduction | 2 | 1998 | 12 | 0.070 |
Why?
|
| Cataract | 1 | 2008 | 12 | 0.070 |
Why?
|
| Hysterectomy | 2 | 2006 | 30 | 0.070 |
Why?
|
| Osteoporosis, Postmenopausal | 2 | 2003 | 43 | 0.070 |
Why?
|
| Computational Biology | 2 | 2018 | 26 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2008 | 141 | 0.060 |
Why?
|
| Cooking | 5 | 2005 | 17 | 0.060 |
Why?
|
| Mice | 2 | 2020 | 82 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2007 | 50 | 0.060 |
Why?
|
| Dinucleoside Phosphates | 1 | 2006 | 2 | 0.060 |
Why?
|
| Food Services | 1 | 1987 | 15 | 0.060 |
Why?
|
| Osteoarthritis, Hip | 1 | 2006 | 8 | 0.060 |
Why?
|
| Endpoint Determination | 1 | 2006 | 10 | 0.060 |
Why?
|
| Osteoarthritis, Knee | 1 | 2006 | 11 | 0.060 |
Why?
|
| Asian Continental Ancestry Group | 3 | 2012 | 87 | 0.060 |
Why?
|
| Microsatellite Repeats | 3 | 2015 | 10 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2018 | 90 | 0.060 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2006 | 7 | 0.060 |
Why?
|
| Blood Pressure | 2 | 2022 | 288 | 0.060 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 7 | 0.060 |
Why?
|
| Carotid Artery Diseases | 1 | 2006 | 11 | 0.060 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2006 | 7 | 0.060 |
Why?
|
| Riboflavin | 3 | 2012 | 3 | 0.060 |
Why?
|
| Vitamin B 6 | 3 | 2012 | 3 | 0.060 |
Why?
|
| Methionine | 3 | 2012 | 5 | 0.060 |
Why?
|
| Vitamin B 12 | 3 | 2012 | 13 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2019 | 3 | 0.060 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 13 | 0.060 |
Why?
|
| Waist Circumference | 1 | 2026 | 34 | 0.060 |
Why?
|
| SEER Program | 2 | 2020 | 92 | 0.060 |
Why?
|
| Estrogen Receptor beta | 1 | 2005 | 10 | 0.060 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2005 | 1 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2005 | 5 | 0.060 |
Why?
|
| Educational Status | 5 | 2009 | 177 | 0.060 |
Why?
|
| Point Mutation | 1 | 2005 | 6 | 0.060 |
Why?
|
| Lumbar Vertebrae | 1 | 2025 | 21 | 0.060 |
Why?
|
| Primary Prevention | 4 | 2006 | 61 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2006 | 101 | 0.060 |
Why?
|
| Receptor, Insulin | 1 | 2005 | 6 | 0.060 |
Why?
|
| Somatomedins | 1 | 2005 | 5 | 0.060 |
Why?
|
| Epoxide Hydrolases | 1 | 2005 | 2 | 0.060 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2005 | 6 | 0.060 |
Why?
|
| Epidemiologic Studies | 2 | 2005 | 29 | 0.060 |
Why?
|
| Edible Grain | 3 | 2012 | 14 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2024 | 2 | 0.060 |
Why?
|
| Statistics as Topic | 3 | 2014 | 57 | 0.050 |
Why?
|
| Hip Fractures | 4 | 2006 | 74 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2024 | 11 | 0.050 |
Why?
|
| Emigrants and Immigrants | 2 | 2015 | 27 | 0.050 |
Why?
|
| Walking Speed | 1 | 2024 | 3 | 0.050 |
Why?
|
| Postural Balance | 1 | 2024 | 14 | 0.050 |
Why?
|
| Sucrose | 2 | 2005 | 6 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2004 | 8 | 0.050 |
Why?
|
| Uterine Hemorrhage | 1 | 2004 | 9 | 0.050 |
Why?
|
| Placebos | 2 | 2014 | 19 | 0.050 |
Why?
|
| Micronutrients | 1 | 2004 | 9 | 0.050 |
Why?
|
| Drinking | 1 | 2004 | 3 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2014 | 36 | 0.050 |
Why?
|
| Tea | 1 | 2003 | 8 | 0.050 |
Why?
|
| Patient Education as Topic | 3 | 2014 | 193 | 0.050 |
Why?
|
| Muscular Atrophy | 1 | 2023 | 2 | 0.050 |
Why?
|
| Preconception Care | 1 | 2014 | 44 | 0.050 |
Why?
|
| Probability | 2 | 2018 | 70 | 0.050 |
Why?
|
| Multiple Organ Failure | 1 | 2023 | 10 | 0.050 |
Why?
|
| Diet Therapy | 1 | 2003 | 9 | 0.050 |
Why?
|
| Medical History Taking | 2 | 2003 | 33 | 0.050 |
Why?
|
| Principal Component Analysis | 2 | 2013 | 24 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 30 | 0.050 |
Why?
|
| Anxiety | 2 | 2014 | 162 | 0.050 |
Why?
|
| Abdomen | 1 | 2022 | 20 | 0.050 |
Why?
|
| F2-Isoprostanes | 1 | 2002 | 1 | 0.050 |
Why?
|
| Malondialdehyde | 1 | 2002 | 2 | 0.050 |
Why?
|
| Exercise Therapy | 2 | 2014 | 75 | 0.050 |
Why?
|
| Lipid Peroxidation | 1 | 2002 | 4 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2002 | 11 | 0.050 |
Why?
|
| Kidney Calculi | 2 | 2006 | 6 | 0.050 |
Why?
|
| Insulin Receptor Substrate Proteins | 3 | 2008 | 4 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2008 | 8 | 0.050 |
Why?
|
| Glucose Intolerance | 1 | 2012 | 46 | 0.050 |
Why?
|
| Blood Pressure Determination | 1 | 2012 | 56 | 0.050 |
Why?
|
| Nutrition Surveys | 2 | 2012 | 55 | 0.040 |
Why?
|
| Fishes | 3 | 2010 | 10 | 0.040 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2011 | 23 | 0.040 |
Why?
|
| Muscles | 1 | 2020 | 3 | 0.040 |
Why?
|
| Coffee | 1 | 2000 | 5 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 20 | 0.040 |
Why?
|
| Antigens, Ly | 1 | 2020 | 1 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 20 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 23 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 59 | 0.040 |
Why?
|
| American Cancer Society | 1 | 2020 | 12 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2010 | 108 | 0.040 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2020 | 9 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2020 | 4 | 0.040 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2020 | 10 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 35 | 0.040 |
Why?
|
| Length of Stay | 1 | 2020 | 182 | 0.040 |
Why?
|
| Selection Bias | 1 | 2019 | 16 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2009 | 4 | 0.040 |
Why?
|
| Cadherins | 2 | 2009 | 5 | 0.040 |
Why?
|
| Carrier Proteins | 2 | 2009 | 12 | 0.040 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 1 | 0.040 |
Why?
|
| DNA Modification Methylases | 1 | 2019 | 2 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2019 | 85 | 0.040 |
Why?
|
| Dental Caries | 1 | 1979 | 14 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2019 | 9 | 0.040 |
Why?
|
| Psychology | 1 | 2019 | 14 | 0.040 |
Why?
|
| Sex Characteristics | 2 | 2003 | 66 | 0.040 |
Why?
|
| Colon | 1 | 2019 | 20 | 0.040 |
Why?
|
| Rectum | 1 | 2019 | 13 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 2 | 2009 | 22 | 0.040 |
Why?
|
| Xanthines | 1 | 1999 | 6 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2019 | 67 | 0.040 |
Why?
|
| Demography | 1 | 2019 | 92 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 19 | 0.040 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2009 | 31 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 46 | 0.040 |
Why?
|
| Social Environment | 1 | 2019 | 84 | 0.040 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2009 | 15 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 5 | 0.040 |
Why?
|
| Reference Standards | 1 | 2018 | 14 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2020 | 163 | 0.040 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 2 | 2008 | 11 | 0.040 |
Why?
|
| Pulmonary Embolism | 2 | 2004 | 46 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 214 | 0.040 |
Why?
|
| Gels | 1 | 2018 | 2 | 0.040 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2018 | 2 | 0.040 |
Why?
|
| Administration, Intravaginal | 1 | 2018 | 2 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2018 | 3 | 0.040 |
Why?
|
| Body Height | 1 | 2018 | 61 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 10 | 0.030 |
Why?
|
| Reference Values | 3 | 2005 | 86 | 0.030 |
Why?
|
| Seafood | 2 | 2010 | 8 | 0.030 |
Why?
|
| Epidemiologic Research Design | 1 | 2008 | 18 | 0.030 |
Why?
|
| Receptors, Ghrelin | 1 | 2017 | 1 | 0.030 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2017 | 2 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 73 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 7 | 0.030 |
Why?
|
| Diet, Vegetarian | 2 | 2009 | 13 | 0.030 |
Why?
|
| Ghrelin | 1 | 2017 | 13 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 85 | 0.030 |
Why?
|
| Food Preferences | 2 | 2009 | 23 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 33 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 23 | 0.030 |
Why?
|
| Ethinyl Estradiol | 1 | 2007 | 4 | 0.030 |
Why?
|
| Health Services | 1 | 1998 | 110 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 27 | 0.030 |
Why?
|
| Sample Size | 2 | 2012 | 27 | 0.030 |
Why?
|
| Arizona | 1 | 2016 | 5 | 0.030 |
Why?
|
| A549 Cells | 1 | 2016 | 1 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2016 | 1 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 1 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 2 | 0.030 |
Why?
|
| Calcium Oxalate | 1 | 1996 | 2 | 0.030 |
Why?
|
| Diet, Protein-Restricted | 1 | 1996 | 2 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 18 | 0.030 |
Why?
|
| Interleukins | 1 | 2016 | 2 | 0.030 |
Why?
|
| Health Care Costs | 1 | 1998 | 211 | 0.030 |
Why?
|
| Confounding Factors (Epidemiology) | 2 | 2006 | 82 | 0.030 |
Why?
|
| Attitude to Health | 2 | 2008 | 147 | 0.030 |
Why?
|
| Meat Products | 2 | 2006 | 3 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 73 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 35 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 43 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Asia | 1 | 2015 | 12 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 24 | 0.030 |
Why?
|
| Meditation | 1 | 2014 | 17 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 38 | 0.030 |
Why?
|
| Postnatal Care | 1 | 2014 | 20 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2014 | 22 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 1993 | 9 | 0.030 |
Why?
|
| Menstrual Cycle | 1 | 1993 | 5 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 26 | 0.030 |
Why?
|
| Child | 2 | 2019 | 2485 | 0.020 |
Why?
|
| Isothiocyanates | 1 | 2013 | 8 | 0.020 |
Why?
|
| Genistein | 1 | 2013 | 1 | 0.020 |
Why?
|
| MCF-7 Cells | 1 | 2013 | 4 | 0.020 |
Why?
|
| Nipples | 1 | 2013 | 2 | 0.020 |
Why?
|
| Phytoestrogens | 1 | 2013 | 7 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2013 | 4 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 4 | 0.020 |
Why?
|
| Hormones | 1 | 2013 | 14 | 0.020 |
Why?
|
| 5-Lipoxygenase-Activating Proteins | 1 | 2013 | 3 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 193 | 0.020 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2013 | 3 | 0.020 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2013 | 3 | 0.020 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2013 | 3 | 0.020 |
Why?
|
| Laminin | 1 | 2012 | 2 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 4 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 32 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2012 | 1 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2012 | 1 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2012 | 1 | 0.020 |
Why?
|
| Glycine Hydroxymethyltransferase | 1 | 2012 | 1 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2012 | 1 | 0.020 |
Why?
|
| Washington | 1 | 2013 | 388 | 0.020 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2002 | 1 | 0.020 |
Why?
|
| HapMap Project | 1 | 2012 | 1 | 0.020 |
Why?
|
| Thrombosis | 1 | 2002 | 14 | 0.020 |
Why?
|
| Indians, North American | 1 | 2012 | 48 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 237 | 0.020 |
Why?
|
| Mutagens | 2 | 2004 | 2 | 0.020 |
Why?
|
| Methods | 1 | 1991 | 4 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2011 | 1 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 1 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 1 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 1 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2011 | 2 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2011 | 2 | 0.020 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2011 | 3 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 5 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 4 | 0.020 |
Why?
|
| Random Allocation | 1 | 1991 | 33 | 0.020 |
Why?
|
| Deuterium | 1 | 2011 | 3 | 0.020 |
Why?
|
| Oxygen Isotopes | 1 | 2011 | 3 | 0.020 |
Why?
|
| Urinalysis | 1 | 2011 | 9 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 259 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2011 | 2 | 0.020 |
Why?
|
| Health Personnel | 1 | 2012 | 135 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 1991 | 60 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 210 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 19 | 0.020 |
Why?
|
| Physical Exertion | 1 | 2010 | 14 | 0.020 |
Why?
|
| Biopsy | 1 | 2010 | 80 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2009 | 2 | 0.020 |
Why?
|
| DNA Glycosylases | 1 | 2009 | 5 | 0.020 |
Why?
|
| Introns | 1 | 2009 | 9 | 0.020 |
Why?
|
| Inactivation, Metabolic | 1 | 2009 | 1 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2009 | 2 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2009 | 2 | 0.020 |
Why?
|
| gamma-Tocopherol | 1 | 2009 | 1 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 45 | 0.020 |
Why?
|
| Language | 1 | 2009 | 52 | 0.020 |
Why?
|
| Nutritional Sciences | 2 | 2001 | 9 | 0.020 |
Why?
|
| Genes, APC | 1 | 2009 | 1 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Social Class | 1 | 2009 | 117 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2009 | 34 | 0.020 |
Why?
|
| Pro-Opiomelanocortin | 1 | 2008 | 1 | 0.020 |
Why?
|
| Exons | 1 | 2008 | 8 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 33 | 0.020 |
Why?
|
| Alcoholic Beverages | 1 | 2008 | 13 | 0.020 |
Why?
|
| Health Services Research | 1 | 2009 | 201 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2008 | 20 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2008 | 22 | 0.020 |
Why?
|
| Geography | 1 | 2008 | 38 | 0.020 |
Why?
|
| Retinal Pigments | 1 | 2008 | 3 | 0.020 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2007 | 2 | 0.020 |
Why?
|
| Diet, Mediterranean | 1 | 2007 | 7 | 0.020 |
Why?
|
| Minority Groups | 1 | 1998 | 104 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 7 | 0.020 |
Why?
|
| Cryptoxanthins | 1 | 2006 | 1 | 0.020 |
Why?
|
| Twins, Dizygotic | 1 | 2006 | 7 | 0.020 |
Why?
|
| Twins, Monozygotic | 1 | 2006 | 11 | 0.020 |
Why?
|
| Trinucleotide Repeats | 1 | 2006 | 1 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 6 | 0.020 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 1987 | 96 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2006 | 18 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2006 | 20 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2006 | 16 | 0.020 |
Why?
|
| Horses | 1 | 2006 | 2 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2006 | 9 | 0.010 |
Why?
|
| Spinal Fractures | 1 | 2006 | 12 | 0.010 |
Why?
|
| Observation | 1 | 2006 | 20 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2006 | 27 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2006 | 45 | 0.010 |
Why?
|
| Reduced Folate Carrier Protein | 1 | 2005 | 1 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2005 | 6 | 0.010 |
Why?
|
| Health | 1 | 2006 | 32 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2005 | 5 | 0.010 |
Why?
|
| Southwestern United States | 1 | 2005 | 4 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 8 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 18 | 0.010 |
Why?
|
| Waist-Hip Ratio | 1 | 2005 | 23 | 0.010 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2004 | 4 | 0.010 |
Why?
|
| Motivation | 1 | 2005 | 112 | 0.010 |
Why?
|
| Beer | 1 | 2004 | 9 | 0.010 |
Why?
|
| North Carolina | 1 | 2004 | 34 | 0.010 |
Why?
|
| Parity | 1 | 2004 | 57 | 0.010 |
Why?
|
| Food Analysis | 1 | 2003 | 5 | 0.010 |
Why?
|
| Hotlines | 1 | 2002 | 10 | 0.010 |
Why?
|
| Brassica | 1 | 2000 | 1 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2000 | 1 | 0.010 |
Why?
|
| Food Coloring Agents | 1 | 1980 | 4 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2000 | 27 | 0.010 |
Why?
|
| Behavior | 1 | 1980 | 18 | 0.010 |
Why?
|
| Age of Onset | 1 | 2000 | 74 | 0.010 |
Why?
|
| Poultry | 1 | 1999 | 2 | 0.010 |
Why?
|
| Carcinogens | 1 | 1999 | 3 | 0.010 |
Why?
|
| Cattle | 1 | 1999 | 10 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1998 | 1 | 0.010 |
Why?
|
| DNA | 1 | 1999 | 26 | 0.010 |
Why?
|
| Family Health | 1 | 1998 | 45 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 1999 | 123 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 1997 | 5 | 0.010 |
Why?
|
| Fluid Therapy | 1 | 1996 | 10 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 1998 | 228 | 0.010 |
Why?
|
| Centers for Medicare and Medicaid Services (U.S.) | 1 | 1995 | 4 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 1995 | 87 | 0.010 |
Why?
|
| Cholesterol, Dietary | 1 | 1994 | 8 | 0.010 |
Why?
|
| Tape Recording | 1 | 1994 | 5 | 0.010 |
Why?
|
| Computers | 1 | 1994 | 5 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1993 | 13 | 0.010 |
Why?
|
| Hospitalization | 1 | 1998 | 831 | 0.010 |
Why?
|
| Skinfold Thickness | 1 | 1992 | 18 | 0.010 |
Why?
|
| Nutritional Requirements | 1 | 1991 | 4 | 0.010 |
Why?
|
| Hyperkinesis | 1 | 1980 | 1 | 0.000 |
Why?
|